Jefferson scientists hope new test will help identify patients with breast cancer carrying hereditary breast cancer genes

May 12, 2001

Researchers at Jefferson Medical College may be close to developing a simple, inexpensive and rapid test to help identify those women with breast cancer who are at greatest risk of carrying a damaged version of BRCA1 or BRCA2, genes predisposing them to the hereditary form of the disease. The genes put women with breast cancer at a much greater risk of developing other cancers in the same or other breast, in addition to ovarian cancer.

If the scientists, led by Bruce C. Turner, M.D., Ph.D., assistant professor of radiation oncology at Jefferson Medical College and the Kimmel Cancer Center of Thomas Jefferson University in Philadelphia, are right, the test will help identify those patients with breast cancer who need to be tested for alterations in these genes. He presents his group's work May 13 at the annual meeting of the American Society of Clinical Oncology in San Francisco.

"This is important because patients with breast cancer who have mutations in BRCA1 or BRCA2 may be better candidates for certain types of therapy," Dr. Turner says. "For example, they may be better candidates for mastectomy than lumpectomy and radiation therapy - also known as breast-conserving therapy. Those patients electing breast conserving therapy need to have constant monitoring not only of their treated breast but also their other breast if they don't have a mastectomy on that side, and also of their ovaries."

Dr. Turner and his colleagues may have an easy way for patients with breast cancer to determine whether they should be tested for alterations in the cancer genes. His team, along with help from scientists at Coulter Pharmaceuticals in San Diego, has devised a test using a special protein called a monoclonal antibody to determine if BRCA1 is damaged.

The antibody serves as a guided missile aimed directly at the protein made by BRCA1. If the antibody fails to find the normal protein, then this suggests that the gene is damaged or missing, and sequencing should be done.

"The thinking is, if we can develop a screening test for women with a diagnosis of breast cancer - a screening test to determine if they have a high probability of harboring an alteration in BRCA1, then we could identify those patients at high risk for inheriting the damaged gene," explains Dr. Turner. "These women would then be counseled to go on to sequencing to find the exact mutation that is causing the cancer."

Currently, women with a family history of breast cancer or ovarian cancer must undergo genetic sequencing to determine if they carry damaged versions of BRCA1 or BRCA2, which raises their risk of cancer to as much as 80 percent over their lifetime. But the testing takes several weeks to complete and can be expensive. Most patients with breast cancer who are at risk for mutations in the genes - about 5 to 10 percent or 10,000 to 20,000 women annually have such mutations - do not undergo sequencing. The researchers stained samples of breast cancer cells that were obtained at the time of biopsy when the initial diagnosis of breast cancer was made with a specially designed antibody to BRCA1. "A breast cancer that carries an altered BRCA1 gene will be negative for the antibody staining because the alteration would prevent the gene from making its protein - you can't pick it up immunohistochemically," Dr. Turner says.

The scientists wanted to find out if those breast cancer samples that did not have stains for BRCA1 also turned out to have BRCA1 mutations when sequenced. They found that of 118 patients with breast cancer, 22 had the mutation. Of those 22, only one had any "immunoreactivity" to the monoclonal antibody and the other 21 breast cancer samples showed no evidence of BRCA1 protein.

In contrast, the majority of breast cancers with normal versions of the BRCA1 gene had high levels of the BRCA1 protein as detected by the antibody test.

"This study suggests that a simple, rapid immunohistochemical test, which is inexpensive, is a reliable screening test to identify patients who are then optimal candidates for sequencing," he says.

Dr. Turner and his group have begun working with Coulter to design a larger, prospective study to examine the effectiveness of such a screening tool and also to design an antibody that is effective in identifying those breast cancer patients with damaged versions of the other breast cancer gene, BRCA2.
-end-
Editors: This information is embargoed for release on May 13, 2001 at 7:45 a.m. PT at the annual meeting of the American Society of Clinical Oncology meeting in San Francisco (Abstract no. 1663)

Contact: Steve Benowitz or
Phyllis Fisher
215-955-6300
After Hours: 215-955-6060

Thomas Jefferson University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.